Drug Trial Radar · NCT07849894
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Jun 23, 2017
Primary completion
Dec 8, 2018
Study completion Dec 8, 2018
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy participants.
Conditions
- Mild to Moderate Psoriasis
- Healthy Volunteers
Interventions
UCB0159Drug
Different dosages will be provided.
PlaceboOther
Placebo will be provided matching UCB0159 to maintain the blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events from the Screening Visit through the Safety-Follow Up VisitTime frame: From Screening Visit through Safety Follow-Up Visit (up to Day 85)
- Cmax: maximum serum concentration of UCB0159Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)
- tmax: time to reach maximum serum concentration of UCB0159Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)
- AUC(0-t): Area under the UCB0159 concentration-time curve from time 0 to time t, time of last quantifiable concentrationTime frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
PS0019 2
Berlin, Germany
PS0019 1
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.